Reliant Technologies, and Palomar Medical Technologies, Announce Launch of a Fractional Technology Licensing Program
12 11월 2008 - 8:00AM
PR Newswire (US)
Program to Offer Licenses to Fundamental Fractional Patent Families
MOUNTAIN VIEW, Calif. and BURLINGTON, Mass., Nov. 11 /PRNewswire/
-- Reliant Technologies, Inc. and Palomar Medical Technologies,
Inc. (NASDAQ:PMTI) today announced the formation of a Fractional
Technology Open Patent Program ("FTOPP") to offer licenses in the
professional field to key intellectual property in the fractional
space. The FTOPP contains six fundamental fractional patent
families including issued patents and pending patent applications
owned or controlled by Reliant, Palomar and Massachusetts General
Hospital ("MGH"). In addition to this program Reliant and Palomar
have entered into certain cross-licenses between the two companies.
Fractional light-based treatments deliver laser or high-powered
light energy in a pattern that leaves untreated areas of skin
between the treated areas of skin. The healthy, untreated areas
promote faster healing of the treated areas and stimulate increased
clinical response as compared to standard full surface treatments.
Clinical studies show fractional treatments can increase both
efficacy and safety. Fractional treatments have quickly become one
of the most widely accepted and sought after new dermatology
treatments. In response, many companies have launched new
fractional products to meet the large market demand. As pioneers of
fractional technology, Reliant, Palomar and MGH are the owners of
the fundamental intellectual property in this area. In order to
encourage further development of fractional products while also
seeking compensation for their early, ground breaking work,
Reliant, Palomar and MGH have created the FTOPP to provide others
in the industry the opportunity to license the necessary
intellectual property. "We are excited to be a part of this
program," said Dr. R. Rox Anderson, director of the Wellman Center
for Photomedicine, Massachusetts General Hospital. "Fractional
treatment is a broad technology that enhances safety and efficacy
over that of traditional light-based aesthetic treatments. Our work
has already helped many people around the world. This program
enables participants to benefit from years of research and continue
development of an important new approach." "Investing in innovation
is key to the success of Reliant Technologies and it is imperative
that Reliant protect the value of its inventions," said Eric Stang,
president and CEO of Reliant Technologies. "By forming this FTOPP
in conjunction with Palomar and MGH, we are making it possible for
companies to access and take advantage of fundamental intellectual
property in the fractional space." "Palomar is recognized as a
technology leader with one of the strongest intellectual property
portfolios and patent enforcement strategies in the industry," said
Joe Caruso, president and CEO of Palomar Medical Technologies. "The
FTOPP presents a compelling collection of intellectual property
assets that are necessary to operate in the fractional space. We
believe companies exploiting fractional technology will find it in
their interest to take an FTOPP license and not risk the
consequences of infringing such a large number of patents." The
FTOPP comprises six patent families, including eleven issued and
pending U.S. patents and applications, along with foreign
counterparts. Included in the FTOPP from Reliant are: U.S. patent
numbers 6,632,219 and 6,059,820 and patent application number
11/250,139 (the "Tankovich-Baranov" patent family named for early
inventors in the fractional space Dr. Nikolai Tankovich and Dr.
Eugene Baranov); U.S. patent application number 10/542,390 (the
"1678" patent family licensed by Reliant from MGH); and U.S. patent
application number 10/367,582 (the "582" patent family). Included
in the FTOPP from Palomar Medical Technologies are: U.S. patent
number 6,997,923 and patent application number 11/235,697 (the
"923" patent family -- jointly owned with and licensed by Palomar
from MGH); and U.S. patent number 6,723,090 and patent application
number 11/408,272 (the "Fiber Laser" patent family). Also included
in the FTOPP from MGH is U.S. patent number 7,331,953 and patent
application number 11/931,232 (the "953" patent family). Recently,
it was announced that Reliant has agreed to join forces with
Thermage, Inc. (NASDAQ:THRM) in a merger expected to close in the
4th quarter 2008. For more information, visit
http://www.fraxel.com/. About Reliant Technologies Reliant
Technologies develops clinical solutions to rejuvenate aging and
environmentally damaged skin. Reliant is dedicated to providing the
most ergonomic and effective products to the global aesthetic
marketplace. The company pioneered the development of fractional
laser resurfacing that relies on novel high-speed scanning systems
and the Intelligent Optical Tracking(R) system to produce safe and
effective results with minimal recovery time. Reliant is based in
Mountain View, Calif. The Fraxel(R) family of products, which
includes the Fraxel re:pair(TM), Fraxel re:store(TM) and Fraxel
re:fine(TM) laser systems, has quickly become the industry standard
for fractional aesthetic skin treatment. Unlike laser devices of
the past, Fraxel brand laser systems treat microscopic volumes of
skin with each unique pulse, leaving the surrounding area intact
for fast healing. Fraxel lasers have received multiple FDA
clearances and have been found safe and effective in treating many
areas of the face and body. The versatility of the product line
ensures that patients can choose the best treatment for various
stages of their lives as their skin care needs evolve. About
Palomar Medical Technologies Palomar is a leading researcher and
developer of light-based systems for cosmetic treatments. Palomar
pioneered the optical hair removal field, when, in 1997, it
introduced the first high-powered laser hair removal system. Since
then, many of the major advances in light-based hair removal have
been based on Palomar technology. In December 2006, Palomar became
the first company to receive a 510(k) over-the-counter (OTC)
clearance from the United States Food and Drug Administration (FDA)
for a new, patented, home use, light-based hair removal device. OTC
clearance allows the product to be marketed and sold directly to
consumers without a prescription. There are now millions of
light-based cosmetic procedures performed around the world every
year in physician offices, clinics, spas and salons. Palomar is
testing many new and exciting applications to further advance the
hair removal market and other cosmetic applications. Palomar is
focused on developing proprietary light-based technology for
introduction to the mass markets. Palomar has granted The Procter
& Gamble Company a non-exclusive License Agreement to certain
patents, technology and FDA documents related to the home-use,
light-based hair removal field for women. In addition, Palomar has
an exclusive development and license agreement with Johnson &
Johnson Consumer Companies to develop and potentially commercialize
home-use, light-based devices for reducing or reshaping body fat
including cellulite, reducing the appearance of skin aging, and
reducing or preventing acne. Reliant Technologies Contacts: Michael
Hromadik Katelyn O'Reilly Reliant Technologies, Inc. Cohn &
Wolfe (650) 605-2294 (310) 526-5511 DATASOURCE: Reliant
Technologies, Inc. CONTACT: Michael Hromadik of Reliant
Technologies, Inc., +1-650-605-2294, ; or Katelyn O'Reilly of Cohn
& Wolfe, +1-310-526-5511, , for Reliant Technologies, Inc. Web
site: http://www.fraxel.com/
Copyright
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024